VolpeMDanserAHMénardJ. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?J Hypertens2012; 30: 647–654.
2.
DahlöfBSeverPSPoulterNR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005; 366: 895–906.
3.
NinomiyaTPerkovicVde GalanBE. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol2009; 20: 1813–1821.
4.
BakrisGLSarafidisPWeirMR. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified analysis of a randomised controlled trial. Lancet2010; 375: 1173–1181.
5.
ParvingHHBrennerBMMcMurrayJJ. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant2009; 24: 1663–1671.
